



# Mass General Brigham

Cooley Dickinson Hospital

(Patient Sticker)

PHYSICIAN ORDER SET :

**BEZLOTOXUMAB**

CDH 208-252 – Approved - Page 1 of 4

Patient: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender: \_\_\_\_\_

Patient Phone #: \_\_\_\_\_ Height: \_\_\_\_\_ Weight: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

Provider Facility Name: \_\_\_\_\_ Provider Facility Address: \_\_\_\_\_

Ordering Provider: \_\_\_\_\_ Date: \_\_\_\_\_

Signature: \_\_\_\_\_

**NOTE: Medication must be approved by Infectious Disease and/or GI**

## Pre-Medications

	Interval	Defer Until	Duration
<input type="checkbox"/> <b>acetaminophen (TYLENOL) tablet 650 mg</b> 650 mg, Oral, Once, Starting at treatment start time, For 1 dose. Administer at least 30 mins prior to principal medication.	Once		1 treatment
<input type="checkbox"/> <b>diphenhydramine (BENADRYL) 12.5 mg/5 mL elixir 25 mg</b> 25 mg, Oral, Once, Starting at treatment start time, For 1 dose. HOLD IF: Given IV. Administer at least 30 mins prior to principal medication.	Once		1 treatment
<input type="checkbox"/> <b>diphenhydramine (BENADRYL) injection 25 mg</b> 25 mg, Intravenous, Once as needed, Patient unable to tolerate PO, Starting when released, For 1 dose. HOLD IF: Given PO. Administer at least 30 mins prior to principal medication.	Once		1 treatment

## Medications

	Interval	Defer Until	Duration
<input type="checkbox"/> <b>Inbelotixumb (ZINPLAVA) 10 mg/kg in sodium chloride 0.9% infusion</b> 10 mg/kg, Intravenous, Administer over 60 Minutes, Once, Starting 30 minutes after treatment start time, For 1 dose. Administer using sterile nonpyrogenic, low-protein binding 0.2 to 5 micron in-line or add-on filter.	Once		1 treatment

**Has this medication been approved by ID and/or GI? (please circle one):** Yes      No

PHYSICIAN ORDER SET :  
**BEZLOTOXUMAB**

CDH 208-252 – Approved - Page 2 of 4

**Catheter Management**

	Interval	Defer Until	Duration
<input type="checkbox"/> <b>Line Access</b> Routine, As needed, Starting when released, Until Specified. As needed. Until Specified. Insert peripheral IV, or access peripheral, or central venous access device to provide treatment.	PRN		PRN
<input type="checkbox"/> <b>alteplase (CATHFLO) 1mg/mL injection 2 mg</b> 2 mg, Intracatheter, As needed, line care, Starting when released. For central venous access device requiring clearance. May repeat once per lumen. For patients greater than 30 kg: 2 mg in 2 mL using a 10 mL syringe. For patient less than or equal to 30 kg: instill a volume equal to 110% of the internal lumen of CVAD, not to exceed 2 mg in 2 mL.	PRN		PRN
<input type="checkbox"/> <b>lidocaine-prilocaine (EMLA) cream</b> Topical, As needed, apply prior to the PIV insertion or port access, Starting when released. For TOPICAL Use only. Allow at least 1 hour (mild dermal procedures) or at least 2 hours (major dermal procedures) for optimum therapeutic effect.	PRN		PRN
<input type="checkbox"/> <b>heparin (PF) 100 unit/mL flush 5 mL</b> 5 mL, Intravenous, As needed, line care, Starting when released	PRN		PRN
<input type="checkbox"/> <b>heparin (PF) 10 unit/mL flush 3 mL</b> 3 mL, Intravenous, As needed, line care, Starting when released	PRN		PRN
<input type="checkbox"/> <b>heparin (PF) 10 unit/mL flush 5 mL</b> 5 mL, Intravenous, As needed, line care, Starting when released	PRN		PRN
<input type="checkbox"/> <b>heparin (PF) 1000 unit/mL catheter injection 2 mL</b> 2 mL, Intracatheter, As needed, APHERESIS LINE CARE ONLY. HEPARIN MUST BE WITHDRAWN FROM EACH LUMEN PRIOR TO FLUSHING OR INFUSING THROUGH THE APHERESIS CATHETER, Starting when released	PRN		PRN
<input type="checkbox"/> <b>sodium chloride (NS) 0.9% syringe flush 3 mL</b> 3 mL, Intravenous, As needed, Line care per institutional guidelines, Starting when released.	PRN		PRN
<input type="checkbox"/> <b>sodium chloride (NS) 0.9% syringe flush 10 mL</b> 10 mL, Intravenous, As needed, Line care per institutional guidelines, Starting when released.	PRN		PRN
<input type="checkbox"/> <b>sodium chloride (NS) 0.9% syringe flush 20 mL</b> 20 mL, Intravenous, As needed, Line care per institutional guidelines, Starting when released.	PRN		PRN
<input type="checkbox"/> <b>sodium chloride 0.9% infusion</b> 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide treatment, Starting when released	PRN		PRN
<input type="checkbox"/> <b>D5W infusion</b> 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide treatment, Starting when released, For 24 hours	PRN		PRN

PHYSICIAN ORDER SET :  
**BEZLOTOXUMAB**

CDH 208-252 – Approved - Page 3 of 4

**Emergency Medications/Anaphylaxis**

	Interval	Defer Until	Duration
<input type="checkbox"/> <b>Provider and Nurse Communication</b> Routine, Once, Starting when released. Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throat swelling, wheezing, respiratory distress, or decreased oxygen saturation. Stop the infusion and treat with epinephrine FIRST. Notify provider and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering adjunct HYPERSENSITIVITY medications as clinically indicated.	PRN		PRN
<input type="checkbox"/> <b>EPINEPHrine (ADRENALIN) injection 0.3 mg</b> 0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for anaphylaxis. May repeat times 1 dose, Starting when released For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine 1:1000 equivalent to 1 mg/mL	PRN		PRN
<input type="checkbox"/> <b>sodium chloride 0.9% bolus 1,000 mL</b> 1,000 mL, Intravenous, Once as needed, Hypotension, Starting when released, For 1 dose	PRN		PRN
<input type="checkbox"/> <b>Oxygen Therapy – Non-Rebreather</b> Routine Select a Mode of Therapy: Non-Rebreather Titrate Oxygen and use the most appropriate device to maintain Target Oxygen saturation during Activity/Titration: Yes Min SpO2 (%): 94	PRN		PRN

**Hypersensitivity**

	Interval	Defer Until	Duration
<input type="checkbox"/> <b>Provider and Nurse Communication</b> Routine, Until discontinued, Starting when released. Until Specified. Treatment for mild-moderate infusion reaction: Stop the infusion, notify provider and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering medications as clinically indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section.	PRN		Until discont'd
<input type="checkbox"/> <b>albuterol 2.5mg/3 mL (0.83%) nebulizer solution</b> 2.5 mg, Nebulization, Once as needed, wheezing, shortness of breath, Starting when released, For 1 dose	PRN		Until discont'd
<input type="checkbox"/> <b>acetaminophen (TYLENOL) tablet 975 mg</b> 975 mg, Oral, Once as needed, fever, Starting at treatment start time, For 1 dose	PRN		Until discont'd
<input type="checkbox"/> <b>diphenhydrAMINE (BENADRYL) injection 25 mg</b> 25 mg, Intravenous, As needed, itching, hives. Begin with 25 mg. If patient has continued reaction, administer 25 mg, Starting when released, For 1 dose	PRN		Until discont'd
<input type="checkbox"/> <b>famotidine (PEPCID) injection 20 mg in sodium chloride 0.9% 100 mL IVPB</b> 20 mg, Intravenous, Administer over 15 Minutes, at 400 mL/hr, Once as needed, Adjunct treatment for mild-moderate, or SEVERE reaction. HOLD IF: given as premed, Starting when released, For 1 dose.	PRN		Until discont'd
<input type="checkbox"/> <b>cetirizine (ZyrTEC) tablet 10 mg</b> 10 mg, Oral, Once as needed, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting at treatment start time, For 1 dose. HOLD IF: given fexofenadine	PRN		Until discont'd
<input type="checkbox"/> <b>fexofenadine (ALLEGRA) tablet 180 mg</b> 180 mg, Oral, Once as needed, Adjunct treatment for mild-moderated, or SEVERE reaction, Starting at treatment start time, For 1 dose. HOLD IF: given cetirizine	PRN		Until discont'd
<input type="checkbox"/> <b>methylprednisolone sodium succinate (PF) (SOLU-Medrol) injection 40 mg</b>	PRN		Until discont'd



PHYSICIAN ORDER SET :  
**BEZLOTOXUMAB**

CDH 208-252 – Approved - Page 4 of 4

40 mg, Intravenous, Once as needed, Adjunct treatment for mild-moderate, or  
SEVERE reaction, Starting when released, For 1 dose



**ondansetron (PF) (ZOFRAN) Injection 4 mg**

PRN

Until discont'd

4 mg, Intravenous, As needed, nausea, vomiting, may repeat x 1 dose, Starting  
when released, For 2 doses